Publication: Cost Variation Analysis of the Oral Drugs used in Dyslipidemia, Available in Nepalese Market
Date
2025
Journal Title
Journal ISSN
Volume Title
Publisher
Rapti Academy of Health Sciences (RAHS)
Abstract
Abstract:
Introduction: Cardiovascular diseases is the topmost cause of disability adjusted life years in Nepal. There are many groups of anti-dyslipidemic drugs available in the market in different brands and strength. This study is to find the cost ratio and cost variation among the different brands available in the market.
Methods: This descriptive cross sectional market survey was conducted from June 2025 to July 2025. The retail price of anti-dyslipidemic drugs from different pharmacies, wholesalers in Nepal was collected. Similarly government published price list was also reviewed. Cost ratio and percentage of cost variation was calculated form the extracted data.
Results: The cost variation between different brands of the drugs used in dyslipidemia was calculated. Highest cost ratio (1:2.16) and cost variation (116.84%) was found for atorvastatin 20mg, followed by atorvastatin 10mg which had cost ratio (1:2.14) and cost variation (114%). Fenofibrate 200mg had cost ratio of (1:1.85) and cost variation (85.6%). Minimum cost variation was observed among the 5mg and 40mg strength of atorvastatin.
Conclusion: Low to high variation in the cost of the same medicine in different doses with different brands were used to treat dyslipidemia. The drug with least cost variation was found to be 5mg strength of atorvastatin and drug with highest cost variation was found to be with 20mg atorvastatin.
Description
Ashish kumar Bhattarai
Department of Pharmacology, Kathmandu Medical College, Duwakot, Bhaktapur, Nepal
Marina Vaidya Shrestha
Department of Community Medicine, Kathmandu Medical College, Sinamangal, Kathmandu, Nepal
Keywords
cost ratio, cost variation, cross-sectional study, dyslipidemia